A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection

Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In this randomized, placebo-controlled trial (the Borte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Soc Nephrol
Main Authors: Eskandary, Farsad, Regele, Heinz, Baumann, Lukas, Bond, Gregor, Kozakowski, Nicolas, Wahrmann, Markus, Hidalgo, Luis G., Haslacher, Helmuth, Kaltenecker, Christopher C., Aretin, Marie-Bernadette, Oberbauer, Rainer, Posch, Martin, Staudenherz, Anton, Handisurya, Ammon, Reeve, Jeff, Halloran, Philip F., Böhmig, Georg A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2018
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791086/
https://ncbi.nlm.nih.gov/pubmed/29242250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2017070818
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados